lindner {twang}

Lindner Center data on 996 PCI patients analyzed by Kereiakes et al. (2000)

Description

These data are adapted from the lindner dataset in the USPS package. The description comes from that package, except for the variable sixMonthSurvive, which is a recode of lifepres

Data from an observational study of 996 patients receiving an initial Percutaneous Coronary Intervention (PCI) at Ohio Heart Health, Christ Hospital, Cincinnati in 1997 and followed for at least 6 months by the staff of the Lindner Center. The patients thought to be more severely diseased were assigned to treatment with abciximab (an expensive, high-molecular-weight IIb/IIIa cascade blocker); in fact, only 298 (29.9 percent) of patients received usual-care-alone with their initial PCI.

Usage

data(lindner)

Format

A data frame of 10 variables collected on 996 patients; no NAs.

lifepres

Mean life years preserved due to survival for at least 6 months following PCI; numeric value of either 11.4 or 0.

cardbill

Cardiac related costs incurred within 6 months of patient's initial PCI; numeric value in 1998 dollars; costs were truncated by death for the 26 patients with lifepres == 0.

abcix

Numeric treatment selection indicator; 0 implies usual PCI care alone; 1 implies usual PCI care deliberately augmented by either planned or rescue treatment with abciximab.

stent

Coronary stent deployment; numeric, with 1 meaning YES and 0 meaning NO.

height

Height in centimeters; numeric integer from 108 to 196.

female

Female gender; numeric, with 1 meaning YES and 0 meaning NO.

diabetic

Diabetes mellitus diagnosis; numeric, with 1 meaning YES and 0 meaning NO.

acutemi

Acute myocardial infarction within the previous 7 days; numeric, with 1 meaning YES and 0 meaning NO.

ejecfrac

Left ejection fraction; numeric value from 0 percent to 90 percent.

ves1proc

Number of vessels involved in the patient's initial PCI procedure; numeric integer from 0 to 5.

sixMonthSurvive

Survival at six months — a recoded version of lifepres.

References

Kereiakes DJ, Obenchain RL, Barber BL, et al. Abciximab provides cost effective survival advantage in high volume interventional practice. Am Heart J 2000; 140: 603-610.

Obenchain RL. (2009) USPSinR.pdf ../R_HOME/library/USPS 40 pages.